LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Up‐dosing of nivolumab may induce serious immune‐related adverse events

Photo from wikipedia

Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or… Click to show full abstract

Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or 240 mg/body every two-three weeks (LOW-dose regimen). In 2020, a new dosage regimen of 480 mg/body of nivolumab every four weeks (HIGH-dose regimen) was approved in Japan.

Keywords: serious immune; may induce; induce serious; immune related; nivolumab may; dosing nivolumab

Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2021

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.